Evaluation of COVID-19 infection in patients with Neuromyelitis optica spectrum disorder (NMOSD): A report from Iran

Mult Scler Relat Disord. 2020 Sep:44:102245. doi: 10.1016/j.msard.2020.102245. Epub 2020 Jun 1.

Authors

Mohammad Ali Sahraian¹, Amirreza Azimi¹, Samira Navardi¹, Nasim Rezaeimanesh¹, Abdorreza Naser Moghadasi²

Affiliations

¹ Multiple Sclerosis Research Center, Neuroscience institute, Tehran University of Medical Sciences, Tehran, Iran.
² Multiple Sclerosis Research Center, Neuroscience institute, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: [email protected].

No abstract available

Publication types

Evaluation Study

MeSH terms

Adult
Aged
COVID-19 / complications
COVID-19 / epidemiology*
Female
Humans
Immunologic Factors / therapeutic use
Iran / epidemiology
Male
Neuromyelitis Optica / complications
Neuromyelitis Optica / drug therapy
Neuromyelitis Optica / epidemiology*
Rituximab / therapeutic use
Young Adult

Substances

Immunologic Factors
Rituximab